Refine
Year of publication
Document Type
- Article (27)
- Working Paper (3)
- Preprint (2)
Language
- English (32)
Has Fulltext
- yes (32)
Is part of the Bibliography
- no (32)
Keywords
- AML (3)
- Acute myeloid leukemia (3)
- regulatory arbitrage (3)
- Capital Markets Union (2)
- Central Counterparties (2)
- Chemotherapy (2)
- EMIR (2)
- European Supervisory Architecture (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Induction chemotherapy (2)
- Survival (2)
- supervisory arbitrage (2)
- ALK-rearranged NSCLC (1)
- Allograft bone block (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Autogenous bone block (1)
- BCOR (1)
- BCORL1 (1)
- BFIS (1)
- Bone marrow (1)
- Bone marrow aspiration (1)
- Brexit (1)
- CBC (1)
- CDI (1)
- CVID (1)
- Cancer chemotherapy (1)
- Capnography (1)
- Clinical Trials and Observations (1)
- Cytogenetics (1)
- Death rates (1)
- Deletion mutation (1)
- ESBL (1)
- Endoscopy (1)
- Enterobacteriaceae (1)
- European Society for Immunodeficiencies (ESID) (1)
- Fevers (1)
- Fluid overload (1)
- German PID-NET registry (1)
- Heavy Ion Experiments (1)
- Hepatocellular carcinoma (1)
- Hospitals (1)
- Hypoxia (1)
- IgG substitution therapy (1)
- IgG4-related disease (1)
- Indeterminate biliary stricture (1)
- Infection (1)
- Integrated Pulmonary Index (1)
- Intensive care treatment (1)
- Karyotypes (1)
- Liver cancer (1)
- Long term result (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Monitoring (1)
- Multidrug-resistant organisms (1)
- Myeloid Neoplasia (1)
- Neutropenia (1)
- PID prevalence (1)
- PKD (1)
- PKD/IC (1)
- PRRT2 (1)
- Percutaneous endoscopic gastrostomy (1)
- Peripheral blood smears (1)
- Pink esthetic score (1)
- Relapse surveillance (1)
- TP53 mutation status (1)
- VRE (1)
- Vacuoles (1)
- acute myeloid leukemia (1)
- bile duct stenosis (1)
- bleeding (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- eosinophilic cholangitis (1)
- familial infantile epilepsy (1)
- financial innovations (1)
- hemiplegic migraine (1)
- induction chemotherapy (1)
- intracranial hemorrhage (1)
- leasing (1)
- loss-of-function (1)
- phenotypic spectrum (1)
- platelet substitution (1)
- primary immunodeficiency (PID) (1)
- primary sclerosing cholangitis (1)
- registry for primary immunodeficiency (1)
- regulation (1)
- risk stratification (1)
- sequential ALK-inhibitor therapy (1)
- survival (1)
Institute
Pathogenic variants in PRRT2, encoding the proline-rich transmembrane protein 2, have been associated with an evolving spectrum of paroxysmal neurologic disorders. Based on a cohort of children with PRRT2-related infantile epilepsy, this study aimed at delineating the broad clinical spectrum of PRRT2-associated phenotypes in these children and their relatives. Only a few recent larger cohort studies are on record and findings from single reports were not confirmed so far. We collected detailed genetic and phenotypic data of 40 previously unreported patients from 36 families. All patients had benign infantile epilepsy and harbored pathogenic variants in PRRT2 (core cohort). Clinical data of 62 family members were included, comprising a cohort of 102 individuals (extended cohort) with PRRT2-associated neurological disease. Additional phenotypes in the cohort of patients with benign sporadic and familial infantile epilepsy consist of movement disorders with paroxysmal kinesigenic dyskinesia in six patients, infantile-onset movement disorders in 2 of 40 individuals, and episodic ataxia after mild head trauma in one girl with bi-allelic variants in PRRT2. The same girl displayed a focal cortical dysplasia upon brain imaging. Familial hemiplegic migraine and migraine with aura were reported in nine families. A single individual developed epilepsy with continuous spikes and waves during sleep. In addition to known variants, we report the novel variant c.843G>T, p.(Trp281Cys) that co-segregated with benign infantile epilepsy and migraine in one family. Our study highlights the variability of clinical presentations of patients harboring pathogenic PRRT2 variants and expands the associated phenotypic spectrum.
Patients with acute myeloid leukemia (AML) are often exposed to broad-spectrum antibiotics and thus at high risk of Clostridioides difficile infections (CDI). As bacterial infections are a common cause for treatment-related mortality in these patients, we conducted a retrospective study to analyze the incidence of CDI and to evaluate risk factors for CDI in a large uniformly treated AML cohort. A total of 415 AML patients undergoing intensive induction chemotherapy between 2007 and 2019 were included in this retrospective analysis. Patients presenting with diarrhea and positive stool testing for toxin-producing Clostridioides difficile were defined to have CDI. CDI was diagnosed in 37 (8.9%) of 415 AML patients with decreasing CDI rates between 2013 and 2019 versus 2007 to 2012. Days with fever, exposition to carbapenems, and glycopeptides were significantly associated with CDI in AML patients. Clinical endpoints such as length of hospital stay, admission to ICU, response rates, and survival were not adversely affected. We identified febrile episodes and exposition to carbapenems and glycopeptides as risk factors for CDI in AML patients undergoing induction chemotherapy, thereby highlighting the importance of interdisciplinary antibiotic stewardship programs guiding treatment strategies in AML patients with infectious complications to carefully balance risks and benefits of anti-infective agents.